ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.
The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
Researchers tracked data from nearly 400 women with complex CAD who underwent treatment with Shockwave Medical's intravascular lithotripsy technology prior to PCI.
Heart tissue samples that spent 30 days at the International Space Station appear to have been weakened by the low gravity conditions in space. This finding has implications for the heart health of astronauts.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, explains some of the key technology and treatment trends he has his eyes on.
The rise of MIS-C during the COVID-19 pandemic alarmed physicians and patients alike, and the exact cause was unclear. Now, new NIH-funded research appears to provide some answers.
Treatment with TriClip has been consistently associated with minimal adverse events and significant improvements in quality of life. This latest update represents data from nearly 100 patients three years after implantation.
